Last reviewed · How we verify
Tiger Balm
Tiger Balm provides topical pain relief and warming sensation through a combination of menthol, camphor, and other essential oils that stimulate sensory receptors and increase local blood flow.
Tiger Balm provides topical pain relief and warming sensation through a combination of menthol, camphor, and other essential oils that stimulate sensory receptors and increase local blood flow. Used for Muscle aches and pains, Joint pain and stiffness, Minor arthritis pain.
At a glance
| Generic name | Tiger Balm |
|---|---|
| Sponsor | Apothyx, Co. |
| Drug class | Topical counter-irritant / rubefacient |
| Target | TRPM8, TRPA1 (transient receptor potential channels) |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Musculoskeletal |
| Phase | FDA-approved |
Mechanism of action
The active ingredients in Tiger Balm, primarily menthol and camphor, activate TRPM8 and TRPA1 cold-sensing receptors on nerve endings, creating a cooling sensation followed by warmth. This counter-irritant effect distracts from underlying pain and the increased blood flow to the area may provide mild anti-inflammatory benefits and muscle relaxation.
Approved indications
- Muscle aches and pains
- Joint pain and stiffness
- Minor arthritis pain
- Headache (topical application to temples)
Common side effects
- Skin irritation or redness at application site
- Burning or stinging sensation
- Allergic contact dermatitis (rare)
Key clinical trials
- A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza (PHASE1)
- Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer (PHASE1)
- A Study to Evaluate the Safety and Tolerability of RAG-18 in Pediatric Patients With Duchenne Muscular Dystrophy (EARLY_PHASE1)
- A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy (PHASE1)
- THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines (PHASE1, PHASE2)
- First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer (PHASE1)
- A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT) (PHASE1)
- Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tiger Balm CI brief — competitive landscape report
- Tiger Balm updates RSS · CI watch RSS
- Apothyx, Co. portfolio CI